𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mitoxantrone versus doxorubicin in advanced breast cancer: A randomized cross-over trial

✍ Scribed by Neidhart, James A.; Gochnour, Diane; Roach, Ralph W.; Steinberg, Jay A.; Young, Donn

Book ID
122399861
Publisher
Elsevier Science
Year
1983
Tongue
English
Weight
346 KB
Volume
10
Category
Article
ISSN
0305-7372

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized trial of doxorubicin, mitox
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study)
✍ John D. Cowan; C. Kent Osborne; James A. Neidhart; Daniel D. Hoff; John J. Const πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 295 KB

New agents with increased activity and/or reduced toxicity are needed for the treatment of advanced breast cancer. The anthracene derivatives mitoxantrone and bisantrene had significant activity and acceptable toxicity in phase II trials. In an ongoing phasc III trial we have now randomized 150 pati

A prospective randomized trial of doxoru
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer
✍ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 481 KB πŸ‘ 2 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea